HypertensionMeta-analysis
Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program
- pooled analysis of four clinical studies
Authors' conclusion
In this large, pooled cohort of Spyral RF-RDN patients, there were significant BP reductions through 36 months with few adverse events. Additionally, nearly 9 out of 10 patients experienced a clinical benefit. These findings suggest the long-term efficacy and safety of RF-RDN across a broad spectrum of patients with uncontrolled hypertension.
Study context
- Population
- Patients with uncontrolled hypertension treated with RF-RDN using the Spyral devicepatients treated with RF-RDN using the Spyral device
- Participants
- 2,137 patients
Pooled result
As reported in the abstract
Number of antihypertensive medications · 36 months
RF-RDN
3.5
mean · SD 1.9
- Baseline number of antihypertensive medications
- 3.8±2.1
Further pooled results
| Outcome | Values |
|---|---|
| Change in office systolic BP (OSBP) · 36 months | RF-RDN mean change −18.1 (SD 23.4) mmHg |
| Change in 24-hour ambulatory systolic BP (ASBP) · 36 months | RF-RDN mean change −13.3 (SD 17.6) mmHg |
| Proportion with reduction in OSBP ≥10 mmHg, ASBP ≥5 mmHg, and/or ≥1 medication · 36 months | RF-RDN 88% |
- Change in office systolic blood pressure (BP) (OSBP) — Baseline OSBP
- 163±23 mmHg
- Change in 24-hour ambulatory systolic BP (ASBP) — Baseline ASBP
- 152±17 mmHg
- Change in office systolic BP (OSBP): p<0.0001
- Change in 24-hour ambulatory systolic BP (ASBP): p<0.0001
Original publication
Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program. EuroIntervention. Published 15 May 2026. doi:10.4244/eij-d-26-00161
Summarised from the published abstract; every number is checked against it